BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
RESEARCH TRIANGLE PARK, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data on the long-term efficacy and safety of ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients across all age groups.
'These data from both clinical trials and real-world settings continue to strengthen the evidence that ORLADEYO is an effective and well-tolerated long-term prophylactic treatment for HAE. Importantly, patients report not only fewer and less severe attacks, but also meaningful improvements in daily functioning and emotional well-being. This contributes to the growing body of evidence supporting the use of ORLADEYO as a long-term prophylactic option for adolescents and adults living with HAE,' said Helen Thackray, chief research and development officer of BioCryst.
The following four studies were presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Glasgow, United Kingdom, from June 13 to 16, 2025.
Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results from APeX-P
The ongoing open-label APeX-P study is evaluating the pharmacokinetic, safety, and effectiveness of berotralstat in children aged 2 to 11 years with HAE. Patients were enrolled into four weight-based cohorts. Cohort 1 received a 150 mg capsule once daily; cohorts 2-4 received once-daily oral granule doses of 108 mg, 96 mg and 78 mg, respectively.
The median age was 8 years (range: 3–11), with disease onset typically between ages 2–6 years. All patients received standard of care (SOC) treatment for 12 weeks prior to the study.
Key results
Eighty-six percent reduction in attacks requiring professional care: attacks dropped from 22 during the 12-week SOC period to three following 12 weeks of berotralstat treatment
Early/rapid and sustained reduction in the rate of HAE attacks requiring on-demand treatment
Mean (SEM) adjusted monthly attack rate decreased from 1.28 (0.25) during SOC to 0.38 (0.13) from day one to week four of berotralstat treatment
Sustained reduction for up to 48 weeks of follow-up
Berotralstat was well tolerated across all cohorts; the most common treatment-emergent adverse events were nasopharyngitis, upper respiratory tract infection, and headache.
Assessment of the Effectiveness and Tolerability of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Findings from the Berolife Study
The Berolife study is an open-label observational study in France which assessed the real-world tolerability and effectiveness of oral once-daily berotralstat (150 mg) in patients with HAE aged >12 years. A total of 82 patients were enrolled, with a mean (SD) age of 40.0 (17.5) years. The mean (SD) baseline attack rate was 1.1 (1.0) attacks per month (median: 0.83), based on the six months prior to enrollment.
Key results
Significant reduction in monthly HAE attacks was observed at six months (in patients with follow-up data (n=37))
Median monthly attack rate decreased from 1.0 to 0.44 attacks after six months of berotralstat treatment
Sustained reductions in attack frequency maintained at 12, 18, and 24 months
Berotralstat was well tolerated throughout the study period
Adverse events were consistent with previous clinical trial data
Impact of Berotralstat on Quality of Life in Patients with Hereditary Angioedema
This analysis assessed the impact of berotralstat on patient-reported quality of life (QoL) outcomes compared to placebo, using pooled data from previous Phase 3 APeX-2 and APeX-J clinical trials which showed that once-daily berotralstat 150 mg significantly reduced the frequency of HAE attacks. This QoL assessment was measured using the validated Angioedema Quality of Life Questionnaire (AE-QoL), which evaluates four key domains: functioning, fatigue/mood, fears/shame, and nutrition.
Key results
Significant improvements in AE-QoL total and domain scores were observed with berotralstat versus placebo at week 24
Benefits sustained through week 96, indicating lasting improvement in daily life
At week 24, 60 percent of patients receiving berotralstat achieved the Minimal Clinically Important Difference (MCID) in AE-QoL total score, compared to 52.4 percent in the placebo group
Over time, the proportion of patients reaching MCID increased in the berotralstat cohort, suggesting progressive and cumulative improvements in QoL alongside reductions in HAE attack frequency
Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group
This qualitative study explored patient experiences with HAE, including their care journey and perceptions of treatment with berotralstat. Focus groups were conducted to gain insight into the real-world impact of berotralstat on patients' daily lives. Seven patients from France, aged 20-70 years, participated in the focus groups. All had been treated with berotralstat for at least six months, with a median age at HAE diagnosis of 28 years. Prior to starting berotralstat, the majority of participants (71 percent) had switched from previous treatments due to long-term tolerability concerns and guidance from health authorities.
Key findings
Participants reported notable improvements in disease control, including reduced frequency and severity of HAE attacks
Minimal side effects were observed
Berotralstat was described as less burdensome and easier to incorporate into daily routines compared to previous therapies
Improved disease management was associated with reduced psychological distress and a greater sense of normalcy, contributing to enhanced quality of life
About ORLADEYO® (berotralstat)ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.
U.S. Indication and Important Safety Information
INDICATIONORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
Limitations of useThe safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.
IMPORTANT SAFETY INFORMATIONAn increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.
The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.
A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C).
Berotralstat is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein. P-gp inducers (eg, rifampin, St. John's wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.
ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.
The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.
There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.
To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information.
About BioCryst PharmaceuticalsBioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
Forward-Looking StatementsThis press release contains forward-looking statements, including statements relating to ORLADEYO safety, performance and effectiveness. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst's ability to successfully implement or maintain its commercialization plans for ORLADEYO; interim results of a clinical trial do not necessarily predict final results; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay, or withdraw market approval for products and product candidates; and BioCryst's ability to successfully manage its growth and compete effectively. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's forward-looking statements.
BCRXW
Contact:John Bluth+1 919 859 7910jbluth@biocryst.com
Niamh Lyons+353 87 7745000nlyons@biocryst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
With rising temperatures in North Carolina, hospitals report uptick of snake bites
CARY, N.C. (WNCN) — Hospitals throughout the central North Carolina said they're seeing more patients with snake bites walking through their doors. Raleigh native Anita McLoud went through the whole experience when she was bitten by a copperhead in her backyard. She never imagined she'd find herself calling 911 in the hospital, and with a venomous bite. After checking on her chickens during a night in August, McLoud said she turned around to walk back to her house when she had a startling surprise. 'One of the first two things I remember learning from my mom is how to identify a copperhead and how to identify poison ivy,' McLoud said. 'Those were the things you needed to know going out of the house. 'I was in my backyard,' she said. 'I had not seen a snake there in 23 years that I lived there and I was wearing flip flops.' 'My first thought was it's a stick. Within a split second, I [realized] that was not a stick. Was it a snake? I turned and there he was.' According to McLoud, medical staff measured the swelling near the bite every 30 minutes. While she never needed antivenom, doctors gave her morphine for the pain. She said the swelling, pain, and discoloration lasted around five-six weeks. 'I was fortunate that way,' McLoud said. 'They told me at the time, only 23% of people who got bit had to receive the antivenom.' According to Duke Health officials, hospitals usually see more than 100 snakebite patients per year across the health system, with the number of cases typically peaking in July. Since April, officials said emergency departments at Duke University, Duke Regional Hospital and Raleigh Regional Hospital have treated 22 bites this season, which staff said typically starts in April. Officials at WakeMed said an emergency department reported nine patients since June 1, six just between June 14 and June 17. Last year, they saw an increase from 15 patients treated for bites in June to 40 in July. UNC Hospitals in Chapel Hill reported 18 patients from March to mid-June, slightly higher than the same time last year. 'The numbers increase as the weather gets warmer, especially when it's hot and more of us work/play in the yard early in the morning or in the evening—when snakes get more active, too,' staff said in a statement. Talena Chavis of Cary, the owner of NC Snake Catcher has studied snakes for nearly 30 years. She said the summer season typically comes with 8-10 calls a day, often to safely move and relocate snakes. 'I actually don't encourage folks to try to ID snakes themselves because Mother Nature throws curveballs,' Chavis said. 'Even with copperheads, the pattern changes a lot.' North Carolina has six venomous snakes. According to Chavis, the copperhead's bite is rarely fatal. 'Every season, copperheads are our number one snake,' Chavis said. 'To say that we have a surplus or even an overpopulation is not is not off topic.' Chavis believes more encounters have been attributed to more growth and development. The species has also adapted to urban and suburban areas. 'They're not really afraid of loud noises,' she said. 'They don't care about fireworks, blowers, lawnmowers. These guys just don't really care because they're an ambush predator.' According to Chavis, most bites happen during night hours when copperheads are searching for heat and their prey. Most the time, she said people just happen to get in the way. Chavis advises people to be more cautious, aware, and put on boots. 'I firmly believe if people wore their boots in the yard and watched where they put their hands, the number of copperhead bites would be cut in half,' she said. Even after her encounter, McLoud said she now works with the reptiles. 'I've really been enjoying it,' McLoud said. 'I wasn't upset with the snake. He's just doing his 'self-defense' thing. If someone stepped on me, I'd probably react as well.' Duke Health officials also continue to share more information about snakebite safety. If bitten, they said to go to your local hospital—never push off the visit. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
11 hours ago
- Yahoo
At least 7 children have died in a hot car in the U.S. this year. Why this happens, according to experts.
Seven children have died in hot cars across the U.S. so far this year. In March, a 4-month-old who was supposed to be dropped off at a babysitter's home in New Jersey was forgotten in a minivan for two hours. Just last week in North Carolina, a 7-month-old was also left inside a hot minivan. It's a preventable tragedy that makes dozens of headlines every spring and summer. Nearly 40 children die in hot cars each year, according to data compiled by Kids and Car Safety, a national nonprofit that fights for child safety in and around vehicles. Since 1990, more than 1,000 kids have died from overheating in a car somewhere in the U.S. In 2024, 39 kids died in hot cars, according to the National Highway Traffic Safety Administration (NHTSA), down from 2018 and 2019, when a record-breaking 53 children died in hot cars. Excluding car crashes, heatstroke is the leading cause of death in vehicles for children 14 and younger. The majority of hot car deaths happen because the driver forgets the child is in the car, according to the NHTSA. The federal agency has found that 47% of these deaths happen when the caregiver has forgotten to drop those children off at day care or school, and it usually happens at the end of the workweek, on Thursdays or Fridays. The second leading cause is when unsupervised children get into unattended vehicles on their own. 'The majority of parents and caregivers are misinformed and would like to believe that they could never 'forget' their child in a vehicle,' Kids and Car Safety notes. 'The most dangerous mistake a parent or caregiver can make is to think leaving a child alone in a vehicle could never happen to them or their family.' Children who get trapped in cars suffer from pediatric vehicular heatstroke, which happens when the child's body temperature rises because of the internal temperature of a car. For example, if the outside temperature is around 70°F, the inside of a car's temperature will increase to over 100°F within the first 30 minutes. A child's body will overheat three to five times faster than an adult's body, according to the Columbia University Irving Medical Center. More often than not, caregivers leave children in hot cars by accident, which is why they're usually not charged with murder, David Diamond, a psychology professor at the University of South Florida, told Yahoo News. Diamond has studied cases of children dying in hot cars for 20 years. 'These are not parents who don't care about their kids,' Diamond said. 'Everyone can relate to forgetting. It's something that we all do.' Diamond says parents leave their kids in overheating cars because of habit and routine. The 'habit brain memory system' kicks in when people perform repetitive tasks almost automatically or without a second thought. Diamond has said that knowing how to ride a bike or tie shoelaces are examples of habit brain memory. 'You're driving home from work, and you've done it hundreds of times by yourself,' Diamond explained to Yahoo News. 'It's your brain's habit memory system that takes you from work to home without even having to think about it. You drive straight home.' Even if parents feel confident that they will remember their child is in the back seat and needs to be dropped off somewhere before they get to the office, the habit brain memory system can overpower that new addition to a routine they've done hundreds of times without the child, Diamond said. He emphasized this is not a 'syndrome' or rare mental disorder, but something most people experience because it's how the brain functions. It does not mean the parent or caregiver doesn't love their child. ''Forgetting' really is the right word,' he said of situations where parents leave their kids in hot cars. But 'forgetting' the child because of routine doesn't alleviate any severity or pain from the experience for those parents. 'It truly is a form of forgetting. And that's as simple as it is. It is a catastrophe." Creating relevant safety laws is crucial to helping parents protect their children in these situations, Amber Rollins, director of Kids and Car Safety, told Yahoo News. Rollins cited data dating back to 1990 that shows children died less frequently from airbags while sitting in the front seat of a car after states made it illegal for kids under 13 to ride in the passenger seat. (It also wasn't required in all states for kids to ride in car seats until 1985.) But as more children were placed in the back seats of cars to avoid airbag deaths, kids were instead dying of heatstroke because they were forgotten in the car. This is why groups like Advocates for Highway and Auto Safety, Safe Kids Worldwide, the Juvenile Products Manufacturers Association and Kids and Car Safety are advocating for it to be mandatory for car manufacturers to build in radar systems that help notify parents if their kids are still sitting in the back seat. Part of the argument for why radar should be built into the cars — instead of tools parents can order online and install themselves— is, as Diamond told Yahoo News, because most people do not believe they would ever forget their child in the back seat of the car and wouldn't buy it. 'The best kind of solution available right now is radar detection,' Rollins said. 'It's a little chip that goes into the headliner or the roof of the vehicle, and it detects micro-movements. … it can tell the difference between an adult and a child based on micro-movements … and so, effectively, it can tell, 'Hey, there's a kid in here and I don't see a grown-up; we've got a problem.'' Kids and Car Safety coordinated with NHTSA on the federal Hot Cars Act, which was passed by the House of Representatives in 2021. The act then evolved into a provision under the Child Safety section in the Infrastructure Investment and Jobs Act, which was signed into law in November 2021. The provision requires that the Secretary of Transportation 'issue a rule that requires all new passenger motor vehicles to be equipped with a child safety alert system.' But, according to Rollins, the NHTSA has not made enough effort to put this rule into effect across all car manufacturers. Some manufacturers do have 'Rear Occupant Alert' systems in place for certain vehicle productions — it's in multiple Hyundai and Kia vehicles — but Rollins thinks the NHTSA should do more. A spokesperson for the NHTSA told Yahoo News that the organization is still conducting studies to ensure that the radar devices currently available are actually effective. A concern is that if the technology is faulty and alerts parents over every small thing in the back of their car, parents might feel inclined to turn it off, Rollins said. The technology needs to exclusively flag if children are unattended in the back of a car. Rollins argued that there are existing detection devices that have passed multiple tests and should be installed. 'The agency will continue to test additional systems as they become available to the public,' the NHTSA spokesperson said. It's common for parents to believe they would never forget their children in the back seat of their car. Here are some tips from Sanford Health on how to ensure you remember your child is in the back. Put something in the back seat of your car with your child that you need before leaving the vehicle, like a cell phone, one of your shoes or an employee badge — something you need when you arrive at your destination. Keep a stuffed animal in your child's car seat and move it to the front of the car while driving your child as a reminder that they are in the car with you. Ask your babysitter or child care provider to give you a call if your child is expected to show up somewhere but hasn't arrived. Always check that your car is locked and inspect it before leaving the premises — even if you're in a rush. This can help you double-check nobody is in the back seat and addresses the second cause of children dying in hot cars, which is when they climb in unattended and unsupervised.
Yahoo
12 hours ago
- Yahoo
At least 6 children have died in a hot car in the U.S. this year. Why this happens, according to experts.
Six children have died in hot cars across the U.S. so far this year. In March, a 4-month-old who was supposed to be dropped off at a babysitter's home in New Jersey was forgotten in a minivan for two hours. Just last week in North Carolina, a 7-month-old was also left inside a hot minivan. It's a preventable tragedy that makes dozens of headlines every spring and summer. Nearly 40 children die in hot cars each year, according to data compiled by Kids and Car Safety, a national nonprofit that fights for child safety in and around vehicles. Since 1990, more than 1,000 kids have died from overheating in a car somewhere in the U.S. In 2024, 39 kids died in hot cars, according to the National Highway Traffic Safety Administration (NHTSA), down from 2018 and 2019, when a record-breaking 53 children died in hot cars. Excluding car crashes, heatstroke is the leading cause of death in vehicles for children 14 and younger. The majority of hot car deaths happen because the driver forgets the child is in the car, according to the NHTSA. The federal agency has found that 47% of these deaths happen when the caregiver has forgotten to drop those children off at day care or school, and it usually happens at the end of the workweek, on Thursdays or Fridays. The second leading cause is when unsupervised children get into unattended vehicles on their own. 'The majority of parents and caregivers are misinformed and would like to believe that they could never 'forget' their child in a vehicle,' Kids and Car Safety notes. 'The most dangerous mistake a parent or caregiver can make is to think leaving a child alone in a vehicle could never happen to them or their family.' Children who get trapped in cars suffer from pediatric vehicular heatstroke, which happens when the child's body temperature rises because of the internal temperature of a car. For example, if the outside temperature is around 70°F, the inside of a car's temperature will increase to over 100°F within the first 30 minutes. A child's body will overheat three to five times faster than an adult's body, according to the Columbia University Irving Medical Center. More often than not, caregivers leave children in hot cars by accident, which is why they're usually not charged with murder, David Diamond, a psychology professor at the University of South Florida, told Yahoo News. Diamond has studied cases of children dying in hot cars for 20 years. 'These are not parents who don't care about their kids,' Diamond said. 'Everyone can relate to forgetting. It's something that we all do.' Diamond says parents leave their kids in overheating cars because of habit and routine. The 'habit brain memory system' kicks in when people perform repetitive tasks almost automatically or without a second thought. Diamond has said that knowing how to ride a bike or tie shoelaces are examples of habit brain memory. 'You're driving home from work, and you've done it hundreds of times by yourself,' Diamond explained to Yahoo News. 'It's your brain's habit memory system that takes you from work to home without even having to think about it. You drive straight home.' Even if parents feel confident that they will remember their child is in the back seat and needs to be dropped off somewhere before they get to the office, the habit brain memory system can overpower that new addition to a routine they've done hundreds of times without the child, Diamond said. He emphasized this is not a 'syndrome' or rare mental disorder, but something most people experience because it's how the brain functions. It does not mean the parent or caregiver doesn't love their child. ''Forgetting' really is the right word,' he said of situations where parents leave their kids in hot cars. But 'forgetting' the child because of routine doesn't alleviate any severity or pain from the experience for those parents. 'It truly is a form of forgetting. And that's as simple as it is. It is a catastrophe." Creating relevant safety laws is crucial to helping parents protect their children in these situations, Amber Rollins, director of Kids and Car Safety, told Yahoo News. Rollins cited data dating back to 1990 that shows children died less frequently from airbags while sitting in the front seat of a car after states made it illegal for kids under 13 to ride in the passenger seat. (It also wasn't required in all states for kids to ride in car seats until 1985.) But as more children were placed in the back seats of cars to avoid airbag deaths, kids were instead dying of heatstroke because they were forgotten in the car. This is why groups like Advocates for Highway and Auto Safety, Safe Kids Worldwide, the Juvenile Products Manufacturers Association and Kids and Car Safety are advocating for it to be mandatory for car manufacturers to build in radar systems that help notify parents if their kids are still sitting in the back seat. Part of the argument for why radar should be built into the cars — instead of tools parents can order online and install themselves— is, as Diamond told Yahoo News, because most people do not believe they would ever forget their child in the back seat of the car and wouldn't buy it. 'The best kind of solution available right now is radar detection,' Rollins said. 'It's a little chip that goes into the headliner or the roof of the vehicle, and it detects micro-movements. … it can tell the difference between an adult and a child based on micro-movements … and so, effectively, it can tell, 'Hey, there's a kid in here and I don't see a grown-up; we've got a problem.'' Kids and Car Safety coordinated with NHTSA on the federal Hot Cars Act, which was passed by the House of Representatives in 2021. The act then evolved into a provision under the Child Safety section in the Infrastructure Investment and Jobs Act, which was signed into law in November 2021. The provision requires that the Secretary of Transportation 'issue a rule that requires all new passenger motor vehicles to be equipped with a child safety alert system.' But, according to Rollins, the NHTSA has not made enough effort to put this rule into effect across all car manufacturers. Some manufacturers do have 'Rear Occupant Alert' systems in place for certain vehicle productions — it's in multiple Hyundai and Kia vehicles — but Rollins thinks the NHTSA should do more. A spokesperson for the NHTSA told Yahoo News that the organization is still conducting studies to ensure that the radar devices currently available are actually effective. A concern is that if the technology is faulty and alerts parents over every small thing in the back of their car, parents might feel inclined to turn it off, Rollins said. The technology needs to exclusively flag if children are unattended in the back of a car. Rollins argued that there are existing detection devices that have passed multiple tests and should be installed. 'The agency will continue to test additional systems as they become available to the public,' the NHTSA spokesperson said. It's common for parents to believe they would never forget their children in the back seat of their car. Here are some tips from Sanford Health on how to ensure you remember your child is in the back. Put something in the back seat of your car with your child that you need before leaving the vehicle, like a cell phone, one of your shoes or an employee badge — something you need when you arrive at your destination. Keep a stuffed animal in your child's car seat and move it to the front of the car while driving your child as a reminder that they are in the car with you. Ask your babysitter or child care provider to give you a call if your child is expected to show up somewhere but hasn't arrived. Always check that your car is locked and inspect it before leaving the premises — even if you're in a rush. This can help you double-check nobody is in the back seat and addresses the second cause of children dying in hot cars, which is when they climb in unattended and unsupervised.
